Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-Jan-24 4:48 PM View:  | Thye Dirk Chief Executive Officer Director | Quince Therapeutics, Inc. (QNCX) | 16-Jan-24 | Option Exercise | 240,530 | $0.79 | $190,791.00 | 54% 448.91K to 689.44K | |
| 14-Dec-23 6:21 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 14-Dec-23 | Purchase | 22,627 | $1.04 | $23,532.10 | < 1% 6.66M to 6.69M | |
| 14-Dec-23 6:21 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 13-Dec-23 | Purchase | 22,627 | $1.00 | $22,627.00 | < 1% 6.64M to 6.66M | |
| 14-Dec-23 6:21 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 12-Dec-23 | Private Purchase | 300 | $1.00 | $300.00 | < 1% 6.6M to 6.6M | |
| 14-Dec-23 6:21 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 12-Dec-23 | Purchase | 22,327 | $1.02 | $22,773.50 | < 1% 6.6M to 6.62M | |
| 07-Dec-23 6:30 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 07-Dec-23 | Purchase | 19,123 | $1.01 | $19,314.20 | < 1% 4.3M to 4.32M | |
| 07-Dec-23 6:30 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 06-Dec-23 | Purchase | 19,123 | $1.02 | $19,505.50 | < 1% 4.28M to 4.3M | |
| 07-Dec-23 6:30 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 05-Dec-23 | Private Purchase | 19,123 | $1.01 | $19,314.20 | < 1% 4.26M to 4.28M | |
| 01-Dec-23 1:38 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 01-Dec-23 | Purchase | 14,378 | $0.94 | $13,515.30 | < 1% 4.24M to 4.26M | |
| 01-Dec-23 1:38 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 30-Nov-23 | Purchase | 14,378 | $0.90 | $12,940.20 | < 1% 4.23M to 4.24M | |
| 01-Dec-23 1:38 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 29-Nov-23 | Private Purchase | 14,378 | $0.98 | $14,090.40 | < 1% 4.22M to 4.23M | |
| 31-Aug-23 6:42 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 31-Aug-23 | Purchase | 41,026 | $1.32 | $54,154.30 | < 1% 4.17M to 4.22M | |
| 31-Aug-23 6:42 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 30-Aug-23 | Private Purchase | 41,026 | $1.31 | $53,744.10 | < 1% 4.13M to 4.17M | |
| 17-Aug-23 6:08 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 17-Aug-23 | Purchase | 24,766 | $1.29 | $31,948.10 | < 1% 4.11M to 4.13M | |
| 17-Aug-23 6:08 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 16-Aug-23 | Purchase | 117,348 | $1.29 | $151,379.00 | 3% 3.99M to 4.11M | |
| 17-Aug-23 6:08 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 15-Aug-23 | Private Purchase | 107,886 | $1.32 | $142,410.00 | 3% 3.88M to 3.99M | |
| 11-Aug-23 4:15 PM View: | Thye Dirk Chief Executive Officer Director | Quince Therapeutics, Inc. (QNCX) | 10-Aug-23 | Private Purchase | 88,000 | $1.26 | $110,880.00 | 24% 360.91K to 448.91K | |
| 09-Aug-23 6:18 PM View: | McLoughlin Margaret Director | Quince Therapeutics, Inc. (QNCX) | 08-Aug-23 | Private Purchase | 8,000 | $1.23 | $9,840.00 | 100% 0 to 8.0K | |
| 09-Aug-23 6:23 PM View: | Thye Dirk Chief Executive Officer Director | Quince Therapeutics, Inc. (QNCX) | 08-Aug-23 | Private Purchase | 80,000 | $1.24 | $99,200.00 | 28% 280.91K to 360.91K | |
| 09-Aug-23 6:21 PM View: | Hannah Brendan Chief Business Officer | Quince Therapeutics, Inc. (QNCX) | 08-Aug-23 | Private Purchase | 71,762 | $1.22 | $87,549.60 | 55% 129.79K to 201.56K | |
| 06-Mar-23 6:55 PM View: | Monohon Ted Chief Accounting Officer & VP | Quince Therapeutics, Inc. (QNCX) | 06-Mar-23 | Sale (Planned) | 1,871 | $0.98 | $1,833.58 | (6%) 29.31K to 27.44K | |
| 07-Dec-22 5:37 PM View: | Monohon Ted Chief Accounting Officer & VP | Quince Therapeutics, Inc. (QNCX) | 05-Dec-22 | Payment of Exercise | 1,640 | $0.72 | $1,180.80 | (5%) 30.95K to 29.31K | |
| 08-Sep-22 5:58 PM View: | Monohon Ted Chief Accounting Officer & VP | Quince Therapeutics, Inc. (QNCX) | 06-Sep-22 | Payment of Exercise | 1,520 | $1.64 | $2,492.80 | (5%) 32.47K to 30.95K | |
| 08-Jun-22 4:10 PM View: | Holsinger Leslie EVP, Preclinical Development | Quince Therapeutics, Inc. (QNCX) | 06-Jun-22 | Payment of Exercise | 10,920 | $2.86 | $31,231.20 | (7%) 159.0K to 148.08K | |
| 08-Jun-22 4:13 PM View: | Monohon Ted Chief Accounting Officer & VP | Quince Therapeutics, Inc. (QNCX) | 06-Jun-22 | Payment of Exercise | 1,529 | $3.12 | $4,770.48 | (4%) 34.0K to 32.47K | |
| 08-Jun-22 4:09 PM View: | McDowell Caryn Gordon Chief Legal & Adm. Officer | Quince Therapeutics, Inc. (QNCX) | 06-Jun-22 | Sale | 10,800 | $2.86 | $30,922.60 | (8%) 133.3K to 122.5K | |
| 08-Jun-22 4:09 PM View: | McDowell Caryn Gordon Chief Legal & Adm. Officer | Quince Therapeutics, Inc. (QNCX) | 06-Jun-22 | Payment of Exercise | 6,700 | $2.86 | $19,183.40 | (5%) 140.0K to 133.3K | |
| 23-May-22 8:17 PM View: | Low Philip S Director | Quince Therapeutics, Inc. (QNCX) | 19-May-22 | Grant | 455,309 | -- | -- | 100% 0 to 455.31K | |
| 23-May-22 8:29 PM View: | Thye Dirk Chief Executive Officer Director | Quince Therapeutics, Inc. (QNCX) | 19-May-22 | Grant | 64,589 | -- | -- | 100% 0 to 64.59K | |
| 23-May-22 8:09 PM View: | Lamond David Director | Quince Therapeutics, Inc. (QNCX) | 19-May-22 | Grant | 200,002 | -- | -- | 5% 3.68M to 3.88M | |
| 23-May-22 8:07 PM View: | Hannah Brendan Chief Business Officer | Quince Therapeutics, Inc. (QNCX) | 19-May-22 | Grant | 16,224 | -- | -- | 100% 0 to 16.22K | |
| 23-May-22 8:17 PM View: | Low Philip S Director | Quince Therapeutics, Inc. (QNCX) | 19-May-22 | Grant | 63,974 | -- | -- | 14% 455.31K to 519.28K | |
| 23-May-22 8:24 PM View: | Smith Karen L. Chief Medical Officer | Quince Therapeutics, Inc. (QNCX) | 19-May-22 | Grant | 24,336 | -- | -- | 100% 0 to 24.34K | |
| 04-Mar-22 5:55 PM View: | Lowe Christopher P. Interim CEO, COO & CFO | Quince Therapeutics, Inc. (QNCX) | 03-Mar-22 | Grant | 175,000 | -- | -- | 194% 90.0K to 265.0K | |
| 04-Mar-22 5:57 PM View: | McDowell Caryn Gordon Chief Legal & Adm. Officer | Quince Therapeutics, Inc. (QNCX) | 03-Mar-22 | Grant | 140,000 | -- | -- | 100% 0 to 140.0K | |
| 04-Mar-22 5:48 PM View: | Holsinger Leslie EVP, Preclinical Development | Quince Therapeutics, Inc. (QNCX) | 03-Mar-22 | Grant | 155,500 | -- | -- | 4443% 3.5K to 159.0K | |
| 04-Mar-22 5:58 PM View: | Monohon Ted Chief Accounting Officer & VP | Quince Therapeutics, Inc. (QNCX) | 03-Mar-22 | Grant | 34,000 | -- | -- | 100% 0 to 34.0K | |
| 04-Mar-22 5:39 PM View: | Detke Michael J. Chief Medical Officer | Quince Therapeutics, Inc. (QNCX) | 03-Mar-22 | Grant | 140,000 | -- | -- | 100% 0 to 140.0K | |
| 19-Nov-21 8:58 PM View: | Lynch Casey Chief Executive Officer Director | Quince Therapeutics, Inc. (QNCX) | 18-Nov-21 | Option Exercise | 60,000 | $0.46 | $27,600.00 | 5% 1.12M to 1.18M | |
| 16-Nov-21 8:17 PM View: | Lowe Christopher P. COO & Chief Financial Officer | Quince Therapeutics, Inc. (QNCX) | 16-Nov-21 | Option Exercise | 30,000 | $2.23 | $66,900.00 | 50% 60.0K to 90.0K | |
| 12-Nov-21 6:47 PM View: | Dominy Stephen S. Chief Scientific Officer Director | Quince Therapeutics, Inc. (QNCX) | 12-Nov-21 | Market Purchase | 763 | $14.40 | $10,987.20 | < 1% 1.44M to 1.44M | 1% |
| 12-Oct-21 5:48 PM View: | McLoughlin Margaret Director | Quince Therapeutics, Inc. (QNCX) | 08-Oct-21 | Option Exercise | 1,000 | $17.00 | $17,000.00 | 100% 0 to 1.0K | |
| 12-Oct-21 5:48 PM View: | McLoughlin Margaret Director | Quince Therapeutics, Inc. (QNCX) | 08-Oct-21 | Market Option Sale (Planned) | 1,000 | $88.93 | $88,930.00 | (100%) 1.0K to 0 | |
| 07-Oct-21 6:24 PM View: | Lowe Christopher P. COO & Chief Financial Officer | Quince Therapeutics, Inc. (QNCX) | 05-Oct-21 | Market Option Sale (Planned) | 4,963 | $98.50 | $488,856.00 | (8%) 64.96K to 60.0K | |
| 07-Oct-21 6:24 PM View: | Lowe Christopher P. COO & Chief Financial Officer | Quince Therapeutics, Inc. (QNCX) | 05-Oct-21 | Option Exercise | 4,963 | $54.85 | $272,221.00 | 8% 60.0K to 64.96K | |
| 18-Aug-21 5:25 PM View: | Lowe Christopher P. COO & Chief Financial Officer | Quince Therapeutics, Inc. (QNCX) | 17-Aug-21 | Option Exercise | 30,000 | $2.23 | $66,900.00 | 100% 30.0K to 60.0K | |
| 18-Aug-21 5:25 PM View: | Lowe Christopher P. COO & Chief Financial Officer | Quince Therapeutics, Inc. (QNCX) | 16-Aug-21 | Market Option Sale (Planned) | 22,000 | $95.31 | $2,096,780.00 | (42%) 52.0K to 30.0K | |
| 18-Aug-21 5:25 PM View: | Lowe Christopher P. COO & Chief Financial Officer | Quince Therapeutics, Inc. (QNCX) | 16-Aug-21 | Option Exercise | 22,000 | $2.23 | $49,060.00 | 73% 30.0K to 52.0K | |
| 07-Jul-21 8:38 PM View: | Detke Michael J. Chief Medical Officer | Quince Therapeutics, Inc. (QNCX) | 07-Jul-21 | Option Exercise | 17,400 | $2.23 | $38,802.00 | 100% 0 to 17.4K | |
| 07-Jul-21 8:38 PM View: | Detke Michael J. Chief Medical Officer | Quince Therapeutics, Inc. (QNCX) | 07-Jul-21 | Market Sale (Planned) | 17,400 | $55.20 | $960,549.00 | (100%) 17.4K to 0 |
